MedTrace Logo

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

NCT06917079 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 387

Last updated 2026-03-23

No results posted yet for this study

Summary

A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.

Conditions

Interventions

DRUG

BBO-11818

Participants will receive assigned dose of BBO-11818 orally (PO)

DRUG

Pembrolizumab

Patients will receive IV pembrolizumab

DRUG

Platinum chemotherapy (cisplatin or carboplatin)

Patients will receive IV platinum chemotherapy (cisplatin or carboplatin)

DRUG

Pemetrexed

Patients will receive IV pemetrexed

DRUG

Cetuximab

Patients will receive IV cetuximab

DRUG

FOLFOX

Patients will receive IV FOLFOX

DRUG

NALIRIFOX

Patients will receive IV NALIRIFOX

DRUG

Gemcitabine

Patients will receive IV Gemcitabine

DRUG

Nab-paclitaxel

Patients will receive IV Nab-Paclitaxel

Sponsors & Collaborators

  • TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-31
Primary Completion
2027-08-31
Completion
2029-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06917079 on ClinicalTrials.gov